7TH JULY 1986

E.L. GREENE

MARIE TATT

R. ROUSELL
L. FRITH

HTLV III SEROCONVERSION IN RECIPIENTS OF BLOOD PRODUCTS

ONE

As I have already indicated, there is concern in the U.K. that HTLV III antibodies are slipping through the screening process and that processes used to eliminate the virus are not totally satisfactory.

We have reason to believe that something is blowing up and that the locally produced factor VIII product is involved.

We should be following up all recipients of our products to provide evidence that our procedures are effective. Is this being done n the U.S.A. or elsewhere?

Please note that there appears to be no concern about the major commercial companies products but we should be in a position to substantiate our claims, both to the customer and to the authorities if they ask for it, with on-going data from clinical use.

Please let me know what, if anything, we are doing in the way of monitoring for seroconversion.

Regards,

Marie Tatt.
MWT/svs